DEATHS ARE DUE AT DEATH CASES PER YEAR TO LIVER …...hepatocellular carcinoma by the numbers...
1
HEPATOCELLULAR CARCINOMA BY THE NUMBERS HEPATOCELLULAR CARCINOMA (HCC) IS THE MOST COMMON TYPE OF PRIMARY LIVER CANCER, ACCOUNTING FOR 90 PERCENT OF ALL LIVER CANCERS. 841,000 APPROXIMATELY PEOPLE AROUND THE WORLD ARE DIAGNOSED WITH LIVER CANCER EACH YEAR APPROXIMATELY 1 IN 12 CANCER DEATHS ARE DUE TO LIVER CANCER LIVER CANCER IS THE FOURTH LEADING CAUSE OF CANCER MORTALITY WORLDWIDE AND OCCURS MORE OFTEN IN MEN THAN WOMEN. 597,000 245,000 CASES PER YEAR MEDIAN AGE 63 67 AT DIAGNOSIS AT DEATH EUROPE CENTRAL AMERICA SOUTH AMERICA AFRICA 64,800 41,900 11,200 24,200 2,900 82,500 AUSTRALIA & NEW ZEALAND NORTH AMERICA ASIA Source: GLOBOCAN 2018 609,600 LIVER CANCER “HOT SPOTS” SURVIVAL RATES HCC IN ADULTS IS OFTEN DIAGNOSED IN LATER STAGES, WHICH RESULTS IN RELATIVELY LOW 5-YEAR SURVIVAL RATES. LIVER CANCER 5-YEAR RELATIVE SURVIVAL RATES BY STAGE AT DIAGNOSIS LOCALIZED 31% DISTANT 3% UNSTAGED 6% BETWEEN 80 AND 90 PERCENT OF ALL HCC CASES WORLDWIDE ARE CAUSED BY INFECTION WITH THE HEPATITIS B VIRUS (HBV) OR HEPATITIS C VIRUS (HCV) COMMON HCC RISK FACTORS HEAVY ALCOHOL USE OBESITY NON-ALCOHOLIC STEATOHEPATITIS (NASH) GENDER TYPE 2 DIABETES RACE/ ETHNICITY CERTAIN GENETIC SYNDROMES CIRRHOSIS CHRONIC HCV/HBV INFECTION SIGNS & SYMPTOMS UNINTENDED WEIGHT LOSS LOSS OF APPETITE NAUSEA OR VOMITING ENLARGED LIVER AND/OR SPLEEN ABDOMINAL PAIN AND/OR SWELLING ITCHING YELLOWING OF THE SKIN AND EYES TREATMENT OPTIONS A PATIENT’S TREATMENT OPTIONS ARE LARGELY DEPENDENT ON STAGE OF DISEASE & MAY INCLUDE: SURGERY RADIATION THERAPY CHEMOTHERAPY IMMUNOTHERAPY TARGETED DRUG THERAPY TUMOR ABLATION OR EMBOLIZATION REGIONAL 11% © 2018 Bristol-Myers Squibb Company
Transcript of DEATHS ARE DUE AT DEATH CASES PER YEAR TO LIVER …...hepatocellular carcinoma by the numbers...
HEPATOCELLULAR CARCINOMA BY THE NUMBERSHEPATOCELLULAR CARCINOMA (HCC) IS THE MOST COMMON TYPE OF
PRIMARY LIVER CANCER, ACCOUNTING FOR 90 PERCENT OF ALL LIVER CANCERS.
841,000APPROXIMATELY
PEOPLE AROUND THE WORLD ARE
DIAGNOSED WITH LIVER CANCER EACH YEAR
APPROXIMATELY 1 IN 12 CANCER DEATHS ARE DUE TO LIVER CANCER
LIVER CANCER IS THE FOURTH LEADING
CAUSE OF CANCER MORTALITY WORLDWIDE
AND OCCURS MORE OFTEN IN MEN THAN WOMEN.
597,000245,000
CASES PER YEAR
MEDIAN AGE
63
67
AT DIAGNOSIS
AT DEATH
EUROPE
CENTRALAMERICA
SOUTH AMERICA
AFRICA64,800
41,900
11,200
24,2002,900
82,500
AUSTRALIA & NEW ZEALAND
NORTH AMERICA
ASIA
Source: GLOBOCAN 2018
609,600
LIVER CANCER “HOT SPOTS” SURVIVAL RATES
HCC IN ADULTS IS OFTEN DIAGNOSED
IN LATER STAGES, WHICH RESULTS IN
RELATIVELY LOW 5-YEAR SURVIVAL RATES.
LIVER CANCER 5-YEAR RELATIVE SURVIVAL RATES BY STAGE AT DIAGNOSIS
LOCALIZED
31%
DISTANT
3%
UNSTAGED
6%
BETWEEN 80 AND 90
PERCENT OF ALL HCC
CASES WORLDWIDE ARE
CAUSED BY INFECTION
WITH THE HEPATITIS B
VIRUS (HBV) OR
HEPATITIS C VIRUS (HCV)
COMMON HCC RISK FACTORS
HEAVYALCOHOL
USE
OBESITY NON-ALCOHOLIC STEATOHEPATITIS
(NASH)
GENDER TYPE 2DIABETES
RACE/ETHNICITY
CERTAINGENETIC
SYNDROMES
CIRRHOSISCHRONICHCV/HBV
INFECTION
SIGNS & SYMPTOMS
UNINTENDED WEIGHT LOSSLOSS OF APPETITENAUSEA OR VOMITINGENLARGED LIVER AND/OR SPLEENABDOMINAL PAIN AND/OR SWELLINGITCHINGYELLOWING OF THE SKIN AND EYES
TREATMENT OPTIONS
A PATIENT’S TREATMENT OPTIONS ARE LARGELY
DEPENDENT ON STAGE OF DISEASE & MAY INCLUDE:
SURGERY RADIATIONTHERAPY
CHEMOTHERAPY IMMUNOTHERAPY TARGETEDDRUG THERAPY
TUMOR ABLATION OR EMBOLIZATION
REGIONAL
11%
© 2018 Bristol-Myers Squibb Company
